Literature DB >> 30558990

Impact of symptomatic atherosclerosis in patients with pulmonary embolism.

Karsten Keller1, Lukas Hobohm2, Thomas Münzel3, Mir Abolfazl Ostad4.   

Abstract

BACKGROUND: Atherosclerosis is associated with increased cardiovascular mortality. Associations between venous thromboembolism and atherosclerosis were recently reported. We aimed to investigate the impact of symptomatic atherosclerosis on adverse outcomes in patients with pulmonary embolism (PE) and to identify significant differences among patients with PE stratified by symptomatic atherosclerosis.
METHODS: Patients were selected by screening the nationwide inpatients sample for PE (ICD-code I26) stratified by symptomatic atherosclerosis (composite of coronary artery disease [ICD-code I25], myocardial infarction [ICD-code I21], ischemic stroke [ICD-code I63], and/or atherosclerotic arterial diseases [ICD-code I70]). We compared PE patients with (PE + Athero) and without (PE - Athero) symptomatic atherosclerosis and analysed the impact of symptomatic atherosclerosis on adverse outcomes.
RESULTS: Overall, 213,995 patients with PE (54.2% females) were included in this analysis. Of these, 30,157 (14.1%) had symptomatic atherosclerosis with age-dependent incline. Deep vein thrombosis or thrombophlebitis (45.1% vs. 36.9%, P < 0.001) was more commonly observed in the PE - Athero group (Odds Ratio (OR) 0.713 [95% CI 0.695-0.731], P < 0.001). In-hospital mortality (12.1% vs. 9.6%, P < 0.001) and adverse in-hospital events (16.8% vs. 12.6%, P < 0.001) were affected by symptomatic atherosclerosis; both in-hospital mortality (OR 1.107 [95% CI 1.061-1.155], P < 0.001) and adverse in-hospital outcomes (OR 1.143 [95%CI 1.102-1.186], P < 0.001) were affected independently of age, gender, comorbidities, and reperfusion treatments.
CONCLUSIONS: Symptomatic atherosclerosis in patients with PE increased with age and was associated with a poorer outcome. Cardiovascular-atherosclerotic diseases might play a major role in thrombus formation in isolated PE.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Heart failure; In-hospital mortality; Isolated pulmonary embolism; Symptomatic atherosclerosis

Mesh:

Year:  2018        PMID: 30558990     DOI: 10.1016/j.ijcard.2018.12.019

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  The Role of Zinc and Copper in Platelet Activation and Pathophysiological Thrombus Formation in Patients with Pulmonary Embolism in the Course of SARS-CoV-2 Infection.

Authors:  Monika Szewc; Agnieszka Markiewicz-Gospodarek; Aleksandra Górska; Zuzanna Chilimoniuk; Mansur Rahnama; Elżbieta Radzikowska-Buchner; Karolina Strzelec-Pawelczak; Jarosław Bakiera; Ryszard Maciejewski
Journal:  Biology (Basel)       Date:  2022-05-14

2.  Atherosclerosis and Its Impact on the Outcomes of Patients with Deep Venous Thrombosis.

Authors:  Karsten Keller; Jürgen H Prochaska; Meike Coldewey; Sebastian Göbel; Volker H Schmitt; Omar Hahad; Alexander Ullmann; Markus Nagler; Heidrun Lamparter; Christine Espinola-Klein; Thomas Münzel; Philipp S Wild
Journal:  Life (Basel)       Date:  2022-05-14

3.  Impact of cardiovascular risk factors on the clinical presentation and survival of pulmonary embolism without identifiable risk factor.

Authors:  Nuria Rodríguez-Núñez; Alberto Ruano-Raviña; Adriana Lama; Lucía Ferreiro; Jorge Ricoy; José M Álvarez-Dobaño; Juan Suárez-Antelo; M Elena Toubes; Carlos Rábade; Antonio Golpe; Tamara Lourido; Francisco Javier González-Barcala; Luis Valdés
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

4.  Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events.

Authors:  Praveen Hariharan; Nicholas Giordano; Alona Muzikansky; Christopher Kabrhel
Journal:  Int J Cardiol       Date:  2021-01-31       Impact factor: 4.164

5.  Venous thromboembolism in patients hospitalized for knee joint replacement surgery.

Authors:  Karsten Keller; Lukas Hobohm; Stefano Barco; Irene Schmidtmann; Thomas Münzel; Martin Engelhardt; Lukas Eckhard; Stavros V Konstantinides; Philipp Drees
Journal:  Sci Rep       Date:  2020-12-31       Impact factor: 4.379

6.  Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients.

Authors:  José A Fernández; Hiroshi Deguchi; Darlene J Elias; John H Griffin
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.